ACE and chronic kidney disease: The proportions of use of β-blockers, renin angiotensin system blockers (angiotensin-converting enzyme inhibitors [ACE-I] and/or angiotensin II receptor blockers [ARB]), and loop diuretics were significantly higher in risk factor-matched CKD patients than in risk factor-matched non-CKD patients (P = 0.03, P = 0.02, P < 0.001, respectively, Table 1).